Bayer Healthcare Probed On Potential Monopoly In China
This article was originally published in PharmAsia News
Executive Summary
The latest in China’s pharma anti-graft investigations reveals that officials recently contacted a Bayer HealthCare office in China on potential anti-monopoly violations.